Dx&Vx said its proprietary circular mRNA anticancer vaccine candidate, designed and synthesized independently by the company, has shown efficacy in preclinical trials.

The preclinical progress results from a collaborative effort between Dx&Vx, NuclixBio, and Pohang University of Science and Technology (POSTECH).

Using NuclixBio's circular mRNA technology and POSTECH's expertise in lipid nanoparticle (LNP) delivery systems, Dx&Vx has synthesized a vaccine candidate aimed primarily at melanoma, with ongoing developments for breast cancer and other malignancies.

In recent cell line tests, the circular mRNA vaccine demonstrated enhanced expression efficacy and anticancer effects compared to linear mRNA, setting the stage for upcoming animal trials.

The company intends to file for substance patents and present its findings at scientific conferences, focusing on circular mRNA technology. It also aims to introduce OVM-200, a recombinant overlapping peptide (ROP)- based anticancer vaccine, within the year.

"The company's collaborations with academic and research institutions at home and abroad are essential for accelerating development and early commercialization of our pipeline," a company official said. "We are also considering licensing its technologies to expedite market entry."